The molecular machinery behind FGF21’s metabolic effects
FGF21 exerts its metabolic effects by activating a heterodimeric receptor complex comprising FGFR1c and the obligate co-receptor β-Klotho (KLB) — and this pairing is non-negotiable for therapeutic activity. As academic literature from the University of Toronto confirms, FGF21 “plays important roles in regulating both glucose and lipid homeostasis via interacting with a heterodimeric receptor complex comprising FGF receptor 1 (FGFR1) and β-Klotho (KLB).” Signaling through this complex drives glucose uptake, lipid oxidation, adiponectin secretion, and adipose tissue browning, making it a highly attractive axis for MASH, dyslipidemia, and metabolic syndrome.
Transcriptional regulation of FGF21 itself adds another layer of therapeutic relevance. Research from the University of Hong Kong identifies PPARα as the primary hepatic inducer of FGF21 expression under fasting and fatty acid loading conditions, with PPARγ acting as a secondary regulator in adipose tissue. FGF21 expression is also induced by the endoplasmic reticulum stress pathway via ATF4 and CHOP transcription factors, as documented by Jilin University — a finding that links FGF21 biology directly to the metabolic stress states characteristic of MASH.
The FGFR1c / β-Klotho (KLB) heterodimeric complex is the functionally essential receptor system mediating FGF21’s metabolic effects. The C-terminal residues of FGF21 are primarily responsible for KLB binding, while N-terminal residues interact with FGFR1c. Both components must be engaged simultaneously for full agonist activity, which is why bispecific approaches targeting both subunits have emerged as an alternative to FGF21 protein analogs.
A critical safety signal also emerges at the receptor level. Research from the University of Alabama reports that FGF21 can signal through FGFR4 in cardiac myocytes, and that chronic elevation promotes concentric cardiac hypertrophy in diabetic mouse models. This finding implicates FGFR4 selectivity or antagonism as a potential safety design consideration for next-generation analogs intended for long-term use — a constraint that is now shaping engineering programs across the field, as reviewed by bodies including NIH-funded research groups.
FGF21 signals through the FGFR1c / β-Klotho (KLB) heterodimeric receptor complex to regulate glucose uptake, lipid oxidation, adiponectin secretion, and adipose tissue browning. PPARα is the primary hepatic transcription factor inducing FGF21 expression under fasting and fatty acid loading conditions.
Why wild-type FGF21 fails and how engineers are fixing it
Wild-type FGF21 is pharmacologically unsuitable as a therapeutic in its native form: it carries a plasma half-life of approximately 30–90 minutes, is susceptible to proteolytic inactivation by fibroblast activation protein (FAP) at the Pro-171/Ser-172 cleavage site, and has a propensity to aggregate during manufacturing. These three liabilities have driven intensive and diversified protein engineering programs across the industry.
The FAP cleavage problem is quantitatively significant. Research from Eli Lilly established that in healthy human volunteers, 10–34% of circulating FGF21 was found to be cleaved after Pro-171 — meaning a substantial fraction of any administered dose is functionally inactive before it can reach target tissues. N-terminal cleavages at Pro-2 and Pro-4, attributed to dipeptidyl peptidases, represent additional inactivation routes. This proteolytic vulnerability is now a core design constraint for every engineering approach in the field.
“In healthy human volunteers, 10–34% of circulating FGF21 was found to be cleaved after Pro-171 — meaning a substantial fraction of any administered dose is functionally inactive before reaching target tissues.”
Eli Lilly’s LY2405319 was among the first systematic solutions: a variant incorporating an engineered disulfide bond (Leu118Cys/Ala134Cys), deletion of four N-terminal residues (HPIP), and a C-terminal Ala-deletion to block FAP cleavage, designed for once-daily dosing. In diabetic non-human primates, LY2405319 demonstrated improvement of metabolic parameters including glucose, body weight, cholesterol, and triglycerides. Amgen independently developed multiple FGF21 muteins targeting proteolytic stability and aggregation resistance, including an Fc-FGF21 N-terminal fusion with two stabilizing point mutations — finding the N-terminal Fc orientation superior for preserving β-Klotho binding and in vivo potency.
Structural mapping from Indiana University using peptide-based Ala-scanning has further refined the engineering target space, identifying the C-terminal residues of FGF21 as primarily responsible for KLB binding and designing enhanced KLB-binding agonist sequences. This structural knowledge now underpins rational design efforts across multiple programs and is consistent with receptor biology frameworks described by Nature-published mechanistic studies.
Wild-type FGF21 has a plasma half-life of approximately 30–90 minutes and is proteolytically inactivated by fibroblast activation protein (FAP) at the Pro-171/Ser-172 cleavage site. In healthy human volunteers, 10–34% of circulating FGF21 is cleaved at Pro-171, rendering it inactive. Engineering strategies to overcome these liabilities include Fc-fusion, PEGylation, albumin-binding derivatives, and point mutations that block FAP cleavage.
Seven therapeutic modalities competing for the same receptor complex
The FGF21 pipeline has diversified well beyond simple protein analogs into at least seven distinct therapeutic modalities, each with a different mechanism for achieving sustained FGFR1c/β-Klotho activation. This diversification reflects both the difficulty of the target and the breadth of commercial interest.
Engineered protein muteins
The foundational approach: point mutations and deletions that block FAP cleavage, reduce aggregation, and improve receptor binding. Eli Lilly’s LY2405319 and Pfizer’s PF-05231023 represent the earliest clinical-stage muteins. Pfizer’s PF-05231023 displays distinct pharmacokinetic asymmetry between the intact C-terminus and N-terminus, characterized through preclinical PK/PD modeling studies. Ambrx advanced site-specific PEGylation using orthogonal biosynthesis incorporating unnatural amino acids to enable chemically homogeneous PEG conjugation, demonstrating enhanced antidiabetic pharmacology in rodents.
Fc-fusion proteins
Fusing FGF21 to the Fc domain of IgG1 exploits FcRn-mediated recycling to dramatically extend half-life. Amgen found that placing the Fc at the N-terminus was superior for preserving β-Klotho binding. Akero Therapeutics’ AKR-001 (efruxifermin) achieves a half-life of 3–3.5 days with weekly dosing. Novartis and Yuhan Corporation also hold active EP patents in this space, with Yuhan’s EP patent updated as recently as 2025.
PEGylated FGF21 analogs
89Bio holds multiple active IL and EP patents on mutant FGF-21 peptide conjugates in which a PEG moiety is attached via a glycosyl linker — a distinct PEGylation strategy designed to improve manufacturing homogeneity and preserve receptor-binding activity. N-terminal PEGylation with mPEG20 kDa-butyraldehyde has also been characterized for anti-diabetic effects in type 2 diabetes rat models.
Albumin-binding derivatives
Novo Nordisk has filed multiple active IL and EP patents on FGF21 derivatives bearing an albumin binder of formula A-B-C-D-E covalently attached to the FGF21 protein, intended to extend half-life through albumin recycling. Novo Nordisk also holds active patents on FGF21 derivatives with engineered cysteine residues at positions 167–181 of mature human FGF21, with side chains displaying high potency toward FGF receptors.
Bispecific receptor agonists
Rather than administering FGF21 protein, bispecific approaches target the FGFR1c/β-Klotho complex directly. Amgen demonstrated that bispecific Avimer polypeptides binding both receptor components with high affinity could mimic FGF21 activity in vitro and in obese cynomolgus monkeys with metabolic improvements comparable to FGF21 itself. Regeneron Pharmaceuticals holds an active EP patent on FGF21 receptor agonists — including bispecific antibodies — capable of simultaneously binding β-Klotho and FGFR1c to activate FGF21 signaling.
Map the full FGF21 patent landscape across all seven modalities with PatSnap Eureka’s AI-powered drug discovery intelligence.
Explore FGF21 Pipeline Data in PatSnap Eureka →mRNA therapeutics
AstraZeneca reported the first example of subcutaneous mRNA therapy encoding human FGF21 demonstrating preclinical efficacy in diet-induced obese mice, achieving therapeutic plasma FGF21 levels with improved pharmacokinetic/pharmacodynamic coverage versus recombinant protein. This modality remains preclinical based on retrieved data but represents a potentially transformative delivery approach that sidesteps protein manufacturing constraints.
FAP inhibition as an indirect FGF21 activating strategy
Since FAP cleaves and inactivates endogenous FGF21 at Pro-171/Ser-172, FAP inhibition has been proposed as a means to amplify endogenous FGF21 activity without administering exogenous protein. The FAP inhibitor talabostat administered in diet-induced obese mice produced decreases in body weight, adiposity, and improved glucose tolerance, with elevated plasma intact FGF21 — and effects dependent on intact FGF21 signaling, as documented by the University of Cincinnati.
Sanofi holds multiple patents across IL, JP, AR, and SG jurisdictions on FGF21-GLP-1R fusion proteins and FGF21/GLP-1R agonist combinations for diabetes, dyslipidemia, obesity, and metabolic syndrome. This combination strategy — pairing FGF21’s lipid and hepatic effects with GLP-1R’s glycemic and appetite effects — represents a distinct differentiation approach beyond single-axis FGF21 receptor activation.
AstraZeneca reported the first example of subcutaneous mRNA therapy encoding human FGF21 demonstrating preclinical efficacy in diet-induced obese mice, achieving therapeutic plasma FGF21 levels with improved pharmacokinetic/pharmacodynamic coverage versus recombinant protein. This modality remains preclinical as of the retrieved dataset.
Who owns the FGF21 patent landscape
Commercial IP activity in the FGF21 space is concentrated among large pharmaceutical companies and specialized biotechs, with academic institutions contributing mechanistic and translational biology rather than patent filings. Amgen is the most prominently represented commercial innovator in the retrieved dataset by both patent and publication count, holding active patents on FGF21 mutants and publishing extensively on Fc-FGF21 fusions, bispecific FGFR1c/β-Klotho Avimers, and adipose tissue mechanisms.
Novo Nordisk holds a broad-coverage IP position in FGF21 half-life extension chemistry, with multiple active IL and EP patents on albumin-binder derivatives and cysteine-site-directed variants. Bristol-Myers Squibb’s patent position is notable for its translational specificity: active claims on modified FGF-21 (pegbelfermin) for NASH include a specific biomarker threshold — serum Pro-C3 greater than 10 ng/mL — for patient stratification, with decreasing Pro-C3 as an on-treatment pharmacodynamic signal of anti-fibrotic efficacy. This level of biomarker integration in patent claims signals a mature translational strategy, consistent with frameworks advocated by EMA guidance on companion diagnostics in liver disease.
Track active patent filings, assignee landscapes, and freedom-to-operate signals across the FGF21 pipeline with PatSnap Eureka.
Analyse FGF21 Patents in PatSnap Eureka →Sanofi’s multi-jurisdiction patent position — spanning IL, JP, AR, and SG — on FGF21-GLP-1R fusion proteins and combination agonists reflects a deliberate geographic coverage strategy across major metabolic disease markets. 89Bio’s focused portfolio on PEG-glycosyl-conjugated mutant FGF-21 peptides for NASH, T2D, and metabolic syndrome represents a specialized biotech IP strategy in next-generation PEGylation chemistry. Regeneron’s bispecific antibody approach, covered by an active EP patent, differentiates from protein analog strategies by targeting the receptor complex rather than mimicking the endogenous ligand — a distinction with potential implications for selectivity and dosing, as noted in patent literature reviewed by WIPO-registered filings.
Bristol-Myers Squibb’s patent on modified FGF-21 (pegbelfermin) for NASH establishes serum Pro-C3 greater than 10 ng/mL as a threshold for patient stratification, with a decrease in Pro-C3 as an on-treatment pharmacodynamic signal of FGF21 anti-fibrotic efficacy. Novartis holds an active EP patent on Fc-FGF21 variant fusion proteins updated as recently as 2024, and Yuhan Corporation holds an active EP patent updated in 2025.
Clinical and translational signals from the pipeline
Pegbelfermin (BMS-986036) from Bristol-Myers Squibb is identified as the most clinically advanced FGF21 program in the retrieved dataset, with active patent coverage specifically for modified FGF-21 in NASH treatment. Akero Therapeutics’ AKR-001 (efruxifermin) provides the most detailed Phase 1 data in the dataset: in a multiple ascending dose study in type 2 diabetes patients, weekly dosing up to 70 mg demonstrated pharmacodynamic effects on serum markers of insulin sensitivity and lipid profiles with acceptable tolerability. The peak-to-trough ratio under steady-state conditions was approximately 2 with weekly dosing, enabled by the 3–3.5 day half-life.
Downstream signaling biology is also being characterized at the translational level. FGF21’s hepatosteatosis-reducing effects — particularly in males — have been linked to downstream stimulation of adiponectin secretion via adrenergic receptor → cAMP → EPAC signaling from white adipose tissue, as documented by AstraZeneca and University of California Davis researchers. Notably, a sex-dependent difference in this pathway was observed, with female mice showing attenuated FGF21 response — a finding with potential implications for clinical trial design and patient stratification. In hepatocytes, FGF21 treatment activates AMP-activated protein kinase (AMPK) to promote fatty acid oxidation and inhibit de novo lipogenesis, reducing intracellular triglyceride accumulation, as characterized by Northwest A&F University.
“A sex-dependent difference in FGF21’s hepatosteatosis-reducing pathway was observed, with female mice showing attenuated FGF21 response — a finding with potential implications for clinical trial design and patient stratification.”
The AMPK activation mechanism is particularly relevant for MASH, where hepatic triglyceride accumulation and de novo lipogenesis are central pathological drivers. This mechanistic grounding — linking FGF21 receptor signaling through AMPK to measurable endpoints — provides the biological rationale for the Pro-C3 biomarker strategy embedded in the BMS patent, and aligns with liver disease endpoints endorsed by the FDA in its NASH drug development guidance. The convergence of mechanistic biology, biomarker development, and engineering innovation positions FGF21 analogs as a scientifically mature, if still commercially unproven, therapeutic class. The absence of any approved FGF21-based therapy — despite programs from Amgen, Novo Nordisk, Bristol-Myers Squibb, Akero, Pfizer, AstraZeneca, Sanofi, Regeneron, 89Bio, Novartis, and Yuhan — underscores both the opportunity and the remaining clinical validation hurdle. Patent intelligence platforms such as PatSnap’s life sciences tools enable R&D teams to monitor this rapidly evolving landscape in real time.